Literature DB >> 11911958

Quantitation of the mRNA levels of Epo and EpoR in various tissues in the ovine fetus.

R Bruce David1, Gaik Bee Lim, Karen M Moritz, Irene Koukoulas, E Marelyn Wintour.   

Abstract

A partial cDNA of the sheep erythropoietin receptor (EpoR) was obtained and used in real-time PCR to quantitate mRNA levels in placenta, liver and kidney throughout development (term=150 days). This was compared with Epo mRNA levels in the same tissues. Both Epo and EpoR mRNA were present in the placenta throughout gestation at low levels from 66 days onwards and these did not vary throughout gestation. Compared with the expression levels in the placenta, the levels of EpoR gene expression in the liver at 66, 99 and 140 days were, median (range)-288 (120-343), 278 (63-541) and 7 (3-15), respectively, reflecting the disappearance of erythropoiesis after 130 days. Low levels of EpoR gene expression were seen in the kidney at 3 (2-5), 5 (2-7), and 7 (2-10) times that in the placenta at 66, 99, and 140 days, respectively. By hybridization histochemistry the EpoR mRNA was located in the proximal tubular cells of the mesonephros and metanephros at 42 days. Epo mRNA levels in the kidney were 215 (116-867), 528 (113-765) and 46 (15-204) times those in the placenta at 69, 99, and 140 days, respectively. In the liver at the same ages the concentrations of mRNA were lower than in the kidney, the liver/placenta ratios being 50 (11-90), 17 (3-39), 9 (5-14). At 130 days Epo/EpoR levels in the hippocampus were 6+/-3 and 8+/-3 times that in the term placenta, respectively. These studies demonstrate that the ovine placenta expresses the Epo gene from at least 66 days of gestation. However, gene expression levels are very low compared with those in the liver and kidney, and even the hippocampus.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11911958     DOI: 10.1016/s0303-7207(01)00718-3

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  7 in total

1.  Maternal nutrient restriction in guinea pigs leads to fetal growth restriction with evidence for chronic hypoxia.

Authors:  Alexander A Elias; Yohei Maki; Brad Matushewski; Karen Nygard; Timothy R H Regnault; Bryan S Richardson
Journal:  Pediatr Res       Date:  2017-05-24       Impact factor: 3.756

2.  Discovery and Characterization of Nonpeptidyl Agonists of the Tissue-Protective Erythropoietin Receptor.

Authors:  James L Miller; Timothy J Church; Dmitri Leonoudakis; Karen Lariosa-Willingham; Normand L Frigon; Connie S Tettenborn; Jeffrey R Spencer; Juha Punnonen
Journal:  Mol Pharmacol       Date:  2015-05-27       Impact factor: 4.436

Review 3.  Role of erythropoietin in the brain.

Authors:  Constance Tom Noguchi; Pundit Asavaritikrai; Ruifeng Teng; Yi Jia
Journal:  Crit Rev Oncol Hematol       Date:  2007-05-04       Impact factor: 6.312

4.  Evidence of receptor-mediated elimination of erythropoietin by analysis of erythropoietin receptor mRNA expression in bone marrow and erythropoietin clearance during anemia.

Authors:  Demet Nalbant; Mohammad Saleh; Frederic D Goldman; John A Widness; Peter Veng-Pedersen
Journal:  J Pharmacol Exp Ther       Date:  2010-01-26       Impact factor: 4.030

5.  The Effect of Size, Maturation, Global Asphyxia, Cerebral Ischemia, and Therapeutic Hypothermia on the Pharmacokinetics of High-Dose Recombinant Erythropoietin in Fetal Sheep.

Authors:  Simerdeep K Dhillon; Guido Wassink; Christopher A Lear; Joanne O Davidson; Nicholas H G Holford; Alistair J Gunn; Laura Bennet
Journal:  Int J Mol Sci       Date:  2020-04-25       Impact factor: 5.923

6.  The effect of erythropoietin on normal and neoplastic cells.

Authors:  Steve Elliott; Angus M Sinclair
Journal:  Biologics       Date:  2012-06-27

7.  The erythropoietin receptor is a downstream effector of Klotho-induced cytoprotection.

Authors:  Ming-Chang Hu; Mingjun Shi; Han J Cho; Jianning Zhang; Alevtina Pavlenco; Shuzhen Liu; Sachdev Sidhu; Lily J-S Huang; Orson W Moe
Journal:  Kidney Int       Date:  2013-05-01       Impact factor: 10.612

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.